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Abstract
Methylphenidate (MPD), commonly known as Ritalin, is the most frequently prescribed drug to treat
children and adults with attention deficit hyperactivity disorder (ADHD). Adolescence is a period
of development involving numerous neuroplasticities throughout the central nervous system (CNS).
Exposure to a psychostimulant such as MPD during this crucial period of neurodevelopment may
cause transient or permanent changes in the CNS. Genetic variability may also influence these
differences. Thus, the objective of the present study was to determine whether acute and chronic
administration of MPD (0.6, 2.5, or 10.0 mg/kg, i.p.) elicit effects among adolescent WKY, SHR,
and SD rats and to compare whether there were strain differences. An automated, computerized,
open-field activity monitoring system was used to study the dose response characteristics of acute
and repeated MPD administration throughout the 11-day experimental protocol. Results showed that
all three adolescent rat groups exhibited dose-response characteristics following acute and chronic
MPD administration, as well as strain differences. These strain differences depended on the MPD
dose and locomotor index. Chronic treatment of MPD in these animals did not elicit behavioral
sensitization, a phenomenon described in adult rats that is characterized by the progressive
augmentation of the locomotor response to repeated administration of the drug. These results suggest
that the animal’s age at time of drug treatment and strain/genetic variability play a crucial role in the
acute and chronic effect of MPD and in the development of behavioral sensitization.
INTRODUCTION
Methylphenidate hydrochloride (MPD) is one of the most prescribed drugs to children and
adults for the treatment of attention deficit hyperactivity disorder [1,32,40,69]. Attention deficit
hyperactivity disorder (ADHD) is a developmental disorder that affects as much as 5 – 15%
of school-aged children in the United States [4,27]. MPD is a stimulant of the central nervous
system (CNS) with a neuropharmacological profile similar to psychostimulants such as
amphetamine and cocaine [29,42]. Cocaine, amphetamine, and MPD are known as indirect
dopamine agonists [11,24,42,61]. There are anectodal reports that catecholerminergic agonists
affect adolescent rats differently as compared to adult rats [5,31,57,63].
*Corresponding author: Nachum.Dafny@uth.tmc.edu, 713-500-5616 (Office), 713-500-2515 (Fax)
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Brain Res Bull. Author manuscript; available in PMC 2007 November 1.
Published in final edited form as:













Studies on behavioral sensitization in animals resulted from chronic amphetamine and cocaine
treatment have yielded conflicting data depending upon the age of the test subject, the drug
dosage, and the intervals between repetitive drug injections [6,31]. Some investigators reported
that younger animals treated chronically with stimulants rarely exhibited behavioral
sensitization [3,8], while others reported the presence of sensitization to the locomotor effects
of cocaine [31]. Since each of the above reports used different rat strains and different drug
regimens of cocaine and amphetamine but none involved MPD, the present study used three
different rat strains of the same age and the same protocol with three different MPD
concentrations for a dose-response assessment and strain comparison.
MATERIALS AND METHODS
ANIMALS
Male spontaneously hyperactive/hypertensive rats (SHR), Wistar-Kyoto (WKY), and Sprague-
Dawley (SD) rats (Total N = 109), 34 to 41 days old, were used for this experiment. Animals
were housed in the experimental room in groups of 4 per cage for adaptation. The ambient
temperature of the room was 21 ± ºC with relative humidity of 37–42%. Animals were
maintained on a 12:12 h light/dark (05:30–17:30 h light on) with food and water given ad
libitum. Animals were kept 5 – 7 days for acclimation. One day prior to the initial recording,
they were randomly divided into groups and individually placed in their testing cage (see Table
1), which became their home cage for the duration of the experiment. Briefly, each rat strain
consisted of 4 groups (each N = 8, unless indicated otherwise). Group I was treated with saline.
Groups II, III, and IV were treated with 0.6, 2.5, or 10.0 mg/kg MPD, i.p., respectively. This
experimental protocol was adapted from previous dose-response experiments of MPD and
amphetamine [19,21,22,65–68].
APPARATUS
The locomotor activity testing chambers consisted of a clear, acrylic, open-field box (40.5 x
40.5 x 31.5 cm) fitted with two arrays of 16 infrared motion sensors, and each located 6 and
12.5 cm above the floor of the box. This system has been previously described in detail [16,
20,21,67]. In short, the activity monitoring system checked each of the sensor beams at a
frequency of 100 Hz to determine whether beams were interrupted. The interruption of any
beam was recorded as an activity score. Interruption of two or more consecutive beams
separated by at least 1 sec was recorded as a movement score. Repeated interruptions of the
same beam(s) were recorded as stereotypic activity. Cumulative counts were compiled and
down loaded every 10 min into the OASIS data collection software that recognized and
differentiated these counts into various locomotor activities indices.
DATA ANALYSIS
All locomotor parameters were evaluated to test for the drug effects during the initial 2 h post-
injection. The acute effect of MPD was calculated as the difference of experimental day 2 from
that of experimental day 1. The chronic effect of MPD was determined by comparing
experimental days 3 – 7 and 11 to experimental day 2 (e.g., sensitization or tolerance). Two
calculations were used: (1) the 2 h data was summed into one value (Fig. 1 and 2) and (2) the
data was summed to 10 min bins where 12 bins were analyzed, i.e., 120 min (see Fig. 3 temporal
graph). These data points were analyzed with repeated ANOVA and Fischer’s LSD post-hoc
test for differences between doses and time effect. Differences in the time course of the effect
for doses were qualitatively described using the 10 min bins data to establish the maximum
effect, time to maximum effect, and duration of the effect for each dose and locomotor index.
Results were analyzed with within-group repeated measures ANOVA (two levels: time post-
injection and experimental day of injection). Post-hoc analysis was conducted with Fischer’s
LSD test at the 0.05 significance level.
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Twenty-four rats were used for saline control groups (N = 8, each strain). Eleven consecutive
locomotor recordings for 23h/day were obtained but only activities of the initial 2 h post-
injection were evaluated. Saline was injected on experimental days 1 to 7 and 11. Data was
collected in 10 min bins and summed into hours. Figure 1 summarizes four locomotor indices
for the initial 2 h post saline injection and showed, for all rat strains (SD, SHR, and WKY),
that saline injection resulted in similar locomotor activity with minor fluctuations from day to
day within strains, i.e., all adolescent rats from the three strains exhibited similar baseline
activity during the day time. Tests of between-subjects effects on the baseline horizontal
activity, total distance, vertical activity, and number of stereotypic movements showed no
significant difference among strains (ANOVA: strain x day). Therefore, data from the initial
day following saline injection in the drug treated groups (experimental day 1) was used as the
control for animal handling and volume of injection. Any significant deviation from this
recording was considered as the drug effect.
MPD ACUTE EFFECT
Three different doses of MPD were used. The first dose of 0.6 mg/kg, i.p., MPD failed to
modulate the four locomotor indices from all of the rat groups. As the MPD doses increased,
differences between the groups were observed (Fig. 2). For example, the 2.5 mg/kg MPD
treatment modulated the horizontal activity of the WKY [F1,25 = 4.69, *P < 0.05] and SD
[F1,15 = 6.96, *P < 0.05] rats. Such increase in horizontal activity of WKY is significantly
greater than that of SHR [F2,32 = 2.48, ▴P < 0.05] when compared among the strains. This
same dose also significantly increased the total distance [F1,25 = 15.47, *P < 0.05; F1,23 = 4.93,
*P < 0.05; F1,15 = 4.26, *P < 0.05], vertical activity [F1,25 = 14.52, *P < 0.05; F1,23 = 11.63,
*P < 0.05; F1,15 = 5.56, *P < 0.05], and number of stereotypic movements [F1,25 = 8.46, *P <
0.05; F1,23 = 8.52, *P < 0.05; F1,15 = 11.11, *P < 0.05] of WKY, SHR, and SD rats, respectively.
When compared among strains, the WKY rats exhibited a significantly greater total distance
than SHR [F2,32 = 6.30; ▴P < 0.05]. Similarly, the 10 mg/kg MPD increased the four locomotor
indices of all three strains (*P < 0.05). However, the intensity of this increase was different
among the rat groups (Fig. 2).
The total distance and vertical activity of WKY rats were significantly greater than that of SD
rats [F2,27 = 3.51; ▴P < 0.05] and SHR [F2,27 = 4.44; ▴P < 0.05], respectively.
CHRONIC EFFECT OF MPD
The dose response data following 0.6, 2.5, and 10.0 mg/kg, i.p., MPD for the 11 experimental
days for adolescent WKY, SHR, and SD rats are summarized in Figures 3, 4, and 5. The left
part of each figure shows the temporal data every 10 min for 2 h post-injection, while the right
part of the figure represents activity summed under the curve from the temporal graph into a
single value for each day, i.e., total horizontal activity during the initial 2 h post injection for
all of the 11 experimental days.
Figure 3 summarizes the horizontal activity of adolescent WKY rats following 0.6, 2.5, and
10.0 mg/kg MPD, i.p., and demonstrates that the lowest MPD dose (0.6 mg/kg) and saline
expressed similar activity level after the initial MPD injection and following five consecutive
daily injection, as well as an injection of the same MPD dose on experimental day 11 after
three days of washout. The 2.5 mg/kg, i.p., MPD on experimental days 2, 7, and 11 elicited a
significant increase in horizontal activity for the initial 30 min post-injection [10 min: F3,51 =
3.87, *P < 0.05; 20 min: F2,51 = 3.64, *P < 0.05; 30 min: F3,51 = 3.80, *P < 0.05] after which
the activity returned to similar baseline level on experimental day 1. Behavioral sensitization
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was not observed (Fig. 3 – temporal graph). When the horizontal activity of 2 h post-injection
of 2.5 mg/kg dose was summed into one value (Fig. 3 – right histograms), the effect of this
MPD dose was observed compared to baseline activity on experimental day 1 (F10,142 = 4.83;
*P < 0.05). Furthermore, the effect of the drug on experimental days 3 to 7 and 11 exhibited
similar increase in activity as the initial MPD dose. The 10.0 mg/kg MPD elicited a robust
increase in horizontal activity for longer duration than the 2.5 mg/kg MPD dose (F10,131 =
33.24; *P < 0.05). The increase in horizontal activity after the initial injection (experimental
day 2; *P < 0.05) was higher and for longer duration time (120 min) compared to experimental
days 7 and 11. On experimental days 7 and 11, the MPD effect was shorter in duration (100
min compared to 120 min) and lower in intensity (Fig. 3 – temporal and bar graphs; ♠P < 0.05).
Similar observations were obtained in the other locomotor indices.
Figure 4 summarizes the horizontal activity of the adolescent SHR following 0.6, 2.5, and 10.0
mg/kg, i.p., MPD and shows that handling of the animals elicited the same increase in activity
for about 10 min whether it was saline or 0.6 mg/kg MPD. There was not any difference
obtained between the activity after saline injection or 0.6 mg/kg MPD during the 2 h post-
injection (Fig. 4 – upper histogram). The middle dose of MPD (2.5 mg/kg) significantly
elevated the horizontal activity for about 40 min post-injection on experimental days 2, 7, and
11 (Fig. 4 – left temporal graph; *P < 0.05). When the horizontal activity for the total 120 min
post-injection was summed into one value for each experimental day, the effect of the drug
was observed in experimental days 4 to 7 (Fig. 4 – right histogram, F10,131 = 3.00; *P < 0.05).
The 10.0 mg/kg, i.p., MPD, which was the highest dose used in this experiment, elicited a
robust increase in horizontal activity for the 120 min post-injection with the most increase in
activity observed in the first 90 min post-injection (Fig. 4 – 10 mg/kg; *P < 0.05). This
augmentation was clearly evident in the bar graph (F10,87 = 14.27; *P < 0.05). Similar
observations were obtained in the other locomotor analyses.
Figure 5 summarizes the horizontal activity recorded from adolescent SD groups following
0.6, 2.5, and 10.0 mg/kg, i.p., MPD. The 0.6 mg/kg MPD did not produce any effect on
horizontal activity, while the 2.5 mg/kg, i.p., MPD increased the horizontal activity
significantly (*P < 0.05) on experimental days 2, 7, and 11 for the initial 50 min. No differences
were obtained when the 2.5 mg/kg MPD was injected to naïve animals (experimental day 2)
or to the same animals injected repeatedly with the drug on experimental day 7 or 11 (Fig. 5 –
temporal graph, 2.5 mg/kg). When the 120 min activity post injection was summed into one
value (total number of activity under the curve of the 120 min), it shows that this dose of MPD
had similar effect on experimental days 3 to 7 and 11 as compared to experimental day 2 but
significantly greater than experimental day 1 (F10,87 = 2.6; *P < 0.05). The 10.0 mg/kg, i.p.,
MPD elicited a robust increase in all locomotor indices of SD rats for 90 min with significant
increases in horizontal activity remained for 120 min post-injection (*P < 0.05). This robust
horizontal activity was similar on experimental day 2, 7, and 11 with some non-significant
fluctuations. In the bar graph, the drug effect of 10.0 mg/kg MPD was evident when compared
to experimental day 1 (F10,87 = 6.21; *P < 0.05). Similar observations were found in the other
locomotor indices (data not shown).
Figure 6 compares the dose-response effect of 0.6, 2.5, or 10.0 mg/kg, i.p., MPD for the
adolescent WKY, SHR, and SD rats as indicated by total distance, vertical activity, and number
of stereotypic movements. In general, the comparison shows some differences among the three
strains but without any specific pattern. For example, the total distance of WKY rats following
2.5 and 10.0 mg/kg MPD on experimental day 2 (drug given to MPD-naïve adolescent animals)
was significantly different when compared to that of SHR and SD rats [F2,32 = 6.30, ▴P < 0.05],
while the same dose of MPD exerted similar effects in vertical activity and number of
stereotypic movements in all three rat strains (Fig. 6). The 0.6 mg/kg MPD on experimental
day 11 [F2,23 = 2.72, ▴P < 0.05] and the 10.0 mg/kg MPD on experimental day 2 [F2,27 = 4.44,
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▴P < 0.05] exhibited different vertical activity level among the rat strains (Fig. 6 – middle
histogram), while the number of stereotypic movements elicited by the three MPD doses was
similar among the strains.
DISCUSSION
The main findings of the present study are that (1) adolescent WKY, SHR, and SD rats exhibited
similar baseline activity during the day time and throughout the 11 experimental days; (2) the
dose-response characteristics to the acute effects of 0.6, 2.5, or 10.0 mg/kg MPD exhibited
incremental increase in locomotor activity, with the intensity of this increase being different
among the rat strains and locomotor indices; (3) similar dose-response characteristics were
observed following chronic administration of 0.6, 2.5, or 10.0 mg/kg MPD; (4) chronic
administration of all three doses of MPD failed to elicit behavioral sensitization or tolerance
in adolescent WKY, SHR, and SD rats; and (5) strain differences were observed following
chronic treatment of MPD as indicated by the total distance traveled and vertical activity of
these animals.
Two data evaluations were performed: (1) temporal profile of the drug effects for every 10 min
bins over the 2 h post-injection and (2) the total activity under the curve of 2 h post injection.
The latter evaluation failed to show that the 2.5 mg/kg dose elicited any effect on locomotion
in all three rat strains. However, the temporal evaluation showed that the 2.5 mg/kg MPD
exerted significant effects for 30, 40, and 50 min post-injection for the WKY, SHR, and SD
rats, respectively. Besides the difference in the duration of the drug effect, there was also
difference in the intensity of the 2.5 mg/kg drug effects between the three adolescent groups
of rats. In contrast, the 10.0 mg/kg MPD elicited similar robust effects on locomotion in all
three strains with some differences in the intensity and time duration of the drug effects. This
observation suggests that dose response protocol and temporal data evaluation is essential in
order to determine whether differences in the response to MPD exist among the rat strains.
The three rat strains used in this study were SD, SHR, and WKY. Each strain of rats comprised
of a different gene pool which could lead to differences in the susceptibility to psychostimulants
and their chronic effects such as sensitization [26,30,47,55]. Because MPD is the drug most
often used for treating adolescents with ADHD, adolescent animal models that exhibit the
ADHD syndrome are one of the most desired choices for studying the effects of MPD [54].
Many animal models for ADHD exist [53,54], including rats selected from a general population
[44], rats reared in social isolation [46], rats exposed to environmental pollutants [28,56], rats
that have undergone neonatal anoxia [13], rats that have undergone hippocampal x-irradiation
in infancy [14], rats that have undergone neurotoxic brain lesions [2], Naples High/Low
excitability rats [50], and knock-out mice [25]. There are also genetic models, including the
SHR, which was bred from progenitor WKY rats [35,37,39,41,51,64]. The SHR strain is a
genetic mutant of WKY, which has led many researchers to use the SHR strain as the animal
model for ADHD and the WKY rats as their control strain. Moreover, the SHR is the only
animal strain hyperactive in a variety of behavioral paradigms and has behavioral
characteristics that are comparable to the behavioral disturbances of children with ADHD and
showing many behavioral characteristics consistent with ADHD, including motor and
cognitive impulsiveness, impaired sustained attention, hyperactivity, and reduced dopamine
(DA) function [49,54,51,59,60].
It seems that the SHR is one of the “best” animal models to study the effects of acute and
chronic MPD treatments, and this rat strain is most frequently used as ADHD model [54,35].
Thus, many investigators are using the SHR strain with the WKY strain as the control in their
investigation of ADHD/MPD studies [39,52,53,54]. Since we used MPD as the
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psychostimulant to elicit sensitization in the present study, the SHR and WKY strains would
provide a good comparison with other studies. Pharmacogenetic research using genetically
deficient rodent strains has provided information about the contribution of genetic factors to
drug related behaviors. There are few reports on genetic/strain differences in determining
vulnerability to different drugs [9,23,33,34,38,43]. Therefore, it is important to investigate and
compare the effects of MPD on another rat strain often used in drug research. In the recent
Medline study of 200 random papers using psychostimulants, it was found that the SD rat strain
was used in 52% of the papers. Thus, we selected the SD rats as an additional genetic/strain
for this study. Moreover, in previous experiments, we studied dose response characteristics of
the acute and chronic effects of MPD and other drugs on locomotor activity of adult SD rats
[19,20,58,67,68]. Therefore, we used SD, WKY, and SHR in this study.
None of our experimental groups exhibited behavioral sensitization, while there were some
reports [3,6,8,31] that showed that adolescent rats exhibited sensitization to the locomotor
activating effects of cocaine. In these experiments, the drug injection and the recording were
performed in test cages, while in the present study drug treatment and recordings were
performed in the rats’ home cages. An additional difference between our finding and the above
observation is the drug. We studied the effects of MPD on adolescent rats; whereas, they studied
a different psychostimulant. Moreover, the definition of adolescent rats varies among the
different published reports. Based on the papers that used rats of different ages and correlated
their ages to that of humans [5,7,10,12,15,17,18,31,36,45,48,57,62], we made the following
determination:
Juvenile Periadolescent Adolescent Young Adult
P-21 to P30 P-31 to P-39 P-40 to P-50 P-60 to P-75
P indicates the post-natal day.
A previous experiment using adult rats of the same three strains and similar protocol reported
that chronic 2.5 mg/kg MPD elicited locomotor sensitization of male WKY and SD rats and
tolerance to the 10.0 mg/kg MPD to all three rat strains [68]. This suggests that the chronic
response to MPD between adult and adolescent rats are different, implying that the ontogeny
of the effects of psychostimulants on the CNS/behavior during the time of neuronal pruning
and adulthood warrants further investigation.
In conclusion, the present study demonstrated that the age at the time of drug treatment and
pharmacokinetic differences in the absorption, distribution and/or metabolism of the drug as
well as strain/genetic variability could significantly influence both the acute and chronic effect
of psychostimulants (e.g., MPD) and the development of behavioral sensitization. Furthermore,
strain/genetic comparisons, such as those performed in the present study, are crucial since in
animal models could simulate the heterogeneity of populations in clinical studies involving
patients.
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summarizes the horizontal activity, total distance traveled, vertical activity, and number of
stereotypic movements for the initial 2 h post saline injection in the morning and showed, for
all rat strains (adolescent SD, SHR, and WKY), that saline injection did not modulate the
locomotor activity over time. Some minor fluctuations from day to day within strains were
observed. Values are presented as the mean ± S.E.M. The days of saline administration are
underlined.
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summarizes the acute dose response of 0.6, 2.5, or 10.0 mg/kg MPD as measured by horizontal
activity, total distance, vertical activity, and number of stereotypic movements obtained from
adolescent WKY, SHR, and SD rats. On experimental day 1, these rats received saline (S),
while they were injected with 0.6 mg/kg MPD (groups M1, M4, and M7), 2.5 mg/kg MPD
(groups M2, M5, and M7), or 10.0 mg/kg MPD (groups M3, M6, and M9) on experimental
day 2. Values are presented as the mean ± S.E.M. The symbol * indicates significant differences
at the level of P < 0.05 when compared to baseline activity on day 1. The ▴ represents significant
differences at the level P < 0.05 in the comparison between rat strains on experimental day 2.
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summarizes the horizontal activity of adolescent WKY rats following saline and chronic MPD
treatment (0.6, 2.5, and 10.0 mg/kg MPD, i.p.). The line graphs show the temporal response
of 10 min samples during the 120 min following post-injection of saline on experimental day
1 or MPD on experimental days 2, 7, and 11. The bar graphs indicate the 2 h cumulative activity
on each experimental day after saline or MPD injection. The line “─” indicates days of MPD
injection. The values are presented as the mean ± S.E.M. The symbol * shows significant
difference at the level of P < 0.05 when experimental days 2, 7, and 11 were compared to
experimental day 1 baseline. The ♠ is indicative of P < 0.05 when experimental days 7 and 11
were compared to experimental day 2.
Yang et al. Page 13














summarizes the horizontal activity of adolescent SHR rats following saline on experimental
day 1 and 0.6, 2.5, and 10.0 mg/kg MPD, i.p., on experimental days 2, 7, and 11. The line
graphs represent the temporal response of 10 min samples during the 120 min following post-
injection of saline or MPD. The bar graphs indicate the 2 h cumulative activity on each day
after saline or MPD injection. The line “─” indicates days of MPD injection. The values are
presented as the mean ± S.E.M. The * indicates P < 0.05 when experimental days 2, 7, and 11
were compared to experimental day 1 baseline.
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summarizes the horizontal activity of adolescent SD rats following saline on experimental day
1 and 0.6, 2.5, and 10.0 mg/kg MPD, i.p., on experimental days 2, 7, and 11. The line graphs
represent the temporal response of 10 min samples during the 120 min following post-injection
of saline or MPD. The bar graphs indicate the 2 h cumulative activity on each day after saline
or MPD injection. The line “─” indicates days of MPD injection. The values are presented as
the mean ± S.E.M. The * shows P < 0.05 when experimental days 2, 7, and 11 were compared
to experimental day 1 baseline.
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compares the dose-response effect of 0.6, 2.5, or 10.0 mg/kg, i.p., MPD for the adolescent
WKY, SHR, and SD rats as indicated by total distance, vertical activity, and number of
stereotypic movements. Values are presented as the mean ± S.E.M. with ▴P < 0.05 when
compared between strains.
Yang et al. Page 16

























Yang et al. Page 17
Table 1
Treatment protocol involving adolescent male rats during the 11 experimental days.
Experimental Day Day 1 Days 2–7 Days 8–10 Day 11
WKY N = 8 Saline Saline Washout Saline
SHR N = 8 “ “ “ “
SD N = 8 “ “ “ “
WKY N = 8 “ 0.6 mg/kg MPD “ 0.6 mg/kg MPD
N = 13 “ 2.5 mg/kg MPD “ 2.5 mg/kg MPD
N = 12 “ 10.0 mg/kg MPD “ 10.0 mg/kg MPD
SHR N = 8 “ 0.6 mg/kg MPD “ 0.6 mg/kg MPD
N = 12 “ 2.5 mg/kg MPD “ 2.5 mg/kg MPD
N = 8 “ 10.0 mg/kg MPD “ 10.0 mg/kg MPD
SD N = 8 “ 0.6 mg/kg MPD “ 0.6 mg/kg MPD
N = 8 “ 2.5 mg/kg MPD “ 2.5 mg/kg MPD
N = 8 “ 10.0 mg/kg MPD “ 10.0 mg/kg MPD
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